REVEALED: Is moderna stock outperforming the dow - The Real Truth

With a market cap of $19.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) medicines, with operations across the United States, Europe, and global markets. Its broad vaccine portfolio spans respiratory diseases (including COVID-19, RSV, influenza, and pandemic influenza), latent and enteric viruses, public health threats such as Zika and Mpox, and bacterial diseases like Lyme disease. 

Companies valued at $10 billion or more are generally considered "large-cap" stocks and Moderna fits this criterion perfectly. Moderna also develops oncology therapeutics ranging from cancer vaccines to T-cell engagers, as well as treatments for rare diseases, including cystic fibrosis and metabolic disorders.